دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 30,000,000 تومان- قیمت ویژه : 6,250,000تومان
دسترسی یکماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 31 ﺭﻭﺯ
قیمت : 3,000,000 تومان- قیمت ویژه : 1,250,000تومان
Monitoring Disease Progression in Patients With Transthyretin Amyloid Cardiomyopathy
doi : 10.1016/j.jchf.2025.102766
Volume 14, Issue 1, January 2026, 102766
Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial
doi : 10.1016/j.jchf.2025.03.006
Volume 14, Issue 1, January 2026, 102439
Demystifying the Impact of Kidney Risk on Finerenone Effects in Heart Failure
doi : 10.1016/j.jchf.2025.102819
Volume 14, Issue 1, January 2026, 102819
Finerenone and NYHA Functional Class in Heart Failure: The FINEARTS-HF Trial
doi : 10.1016/j.jchf.2025.03.007
Volume 14, Issue 1, January 2026, 102440
Finerenone: Triumph or Vindication?
doi : 10.1016/j.jchf.2025.102760
Volume 14, Issue 1, January 2026, 102760
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure
doi : 10.1016/j.jchf.2025.102706
Volume 14, Issue 1, January 2026, 102706
Fulfilling the Promise of Cyclic GMP Signaling in Heart Failure With Reduced Ejection Fraction
doi : 10.1016/j.jchf.2025.102773
Volume 14, Issue 1, January 2026, 102773
Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial
doi : 10.1016/j.jchf.2025.102723
Volume 14, Issue 1, January 2026, 102723
Cardiac Progenitor Cells in HLHS: Feasibility Now, Efficacy Next?
doi : 10.1016/j.jchf.2025.102774
Volume 14, Issue 1, January 2026, 102774
Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection: An Analysis of the Surveillance HeartCare Outcomes Registry
doi : 10.1016/j.jchf.2025.102716
Volume 14, Issue 1, January 2026, 102716
A Biopsy-Free Future: Science Fiction or Science Reality?
doi : 10.1016/j.jchf.2025.102782
Volume 14, Issue 1, January 2026, 102782
Sex Differences in Diabetic Cardiomyopathy and Treatment Response to AT-001: Insights From the ARISE-HF Study
doi : 10.1016/j.jchf.2025.02.015
Volume 14, Issue 1, January 2026, 102433
“Arising” Above Heart Failure: Sex Differences in Diabetic Cardiomyopathy
doi : 10.1016/j.jchf.2025.03.021
Volume 14, Issue 1, January 2026, 102460
Beyond the Pump: Reframing Cardiogenic Shock in Heart Failure Through a Multisystem Mechanistic Lens
doi : 10.1016/j.jchf.2025.102711
Volume 14, Issue 1, January 2026, 102711
Cascade Screening in DCM: Where Are We in 2026?
doi : 10.1016/j.jchf.2025.102754
Volume 14, Issue 1, January 2026, 102754
Beyond Body Mass Index in Heart Transplantation: More Than Meets the Eye
doi : 10.1016/j.jchf.2025.102764
Volume 14, Issue 1, January 2026, 102764
The Importance of Being Entresto
doi : 10.1016/j.jchf.2025.102762
Volume 14, Issue 1, January 2026, 102762
All-Cause and Cardiovascular Mortality Among U.S. Adults With Preclinical Heart Failure: NHANES 1999-2018
doi : 10.1016/j.jchf.2025.03.018
Volume 14, Issue 1, January 2026, 102457
The Prehospital Phase of Acute Heart Failure Care: A Population-Based Cohort Study
doi : 10.1016/j.jchf.2025.102603
Volume 14, Issue 1, January 2026, 102603
Incident Heart Failure in Adults With Mild to Moderate Chronic Kidney Disease
doi : 10.1016/j.jchf.2025.102616
Volume 14, Issue 1, January 2026, 102616
Rapid Titration of Heart Failure Therapies by Etiology: An Analysis of STRONG-HF
doi : 10.1016/j.jchf.2025.102615
Volume 14, Issue 1, January 2026, 102615
Streamlined Heart Failure Optimization Protocol for Patients With Reduced Left Ventricular Ejection Fraction: Insights From the SHORT Trial
doi : 10.1016/j.jchf.2025.102663
Volume 14, Issue 1, January 2026, 102663
Toward a Streamlined Optimization Protocol for Patients With Heart Failure With Reduced Ejection Fraction: Emerging Evidence
doi : 10.1016/j.jchf.2025.102724
Volume 14, Issue 1, January 2026, 102724
Rapid Uptitration of Guideline-Directed Medical Therapy for Heart Failure: Speed Means Little Without Direction
doi : 10.1016/j.jchf.2025.102730
Volume 14, Issue 1, January 2026, 102730
Equally Effective in CASTLE-HTx: A Reassuring Signal, Not Definitive Proof
doi : 10.1016/j.jchf.2025.102708
Volume 14, Issue 1, January 2026, 102708
REPLY: Equally Effective in CASTLE-HTx: A Reassuring Signal, Not Definitive Proof
doi : 10.1016/j.jchf.2025.102709
Volume 14, Issue 1, January 2026, 102709
From Small Cavities to Big Gains: Phosphodiesterase 5 Inhibitors in LVAD Care
doi : 10.1016/j.jchf.2025.102756
Volume 14, Issue 1, January 2026, 102756
Reply: From Small Cavities to Big Gains: Phosphodiesterase 5 Inhibitors in LVAD Care
doi : 10.1016/j.jchf.2025.102757
Volume 14, Issue 1, January 2026, 102757
Limits of Agreement for Noninvasive and Invasive Intracardiac Pressure Measurements
doi : 10.1016/j.jchf.2025.102741
Volume 14, Issue 1, January 2026, 102741
Real-World Challenges for Noninvasive Hemodynamic Monitoring in Heart Failure
doi : 10.1016/j.jchf.2025.102739
Volume 14, Issue 1, January 2026, 102739
REPLY: Real-World Challenges for Noninvasive Hemodynamic Monitoring in Heart Failure
doi : 10.1016/j.jchf.2025.102750
Volume 14, Issue 1, January 2026, 102750
NEXN-Related Cardiomyopathy: Expanding the Clinical and Mechanistic Spectrum
doi : 10.1016/j.jchf.2025.102736
Volume 14, Issue 1, January 2026, 102736
Population Stratification and Heterogeneity in NEXN Studies: NEXN Study Limitations
doi : 10.1016/j.jchf.2025.102735
Volume 14, Issue 1, January 2026, 102735
REPLY: On Nexilin-Related Cardiomyopathy
doi : 10.1016/j.jchf.2025.102738
Volume 14, Issue 1, January 2026, 102738
